Tempus AI came into this print with a premium story stock valuation and a share price that had already slipped 29% over the past month. The Q2 numbers landed with a muted 1 day move, as the stock eased about 1%, but the headline inside the release was far louder than the tape. Tempus AI flipped to a US$5.6m quarterly profit on US$382.5m of revenue, and management leaned hard into a cleaner balance sheet after issuing US$460m of zero coupon convertible notes to wipe out a costly loan.

Love the cleaner balance sheet and fresh profitability at Tempus AI but want stocks that already pair AI growth with more mature fundamentals? Check out our shortlist of 69 profitable AI stocks that aren't just burning cash.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$382.5m vs. US$314.6m (up about 22% year on year)
• Net Income, Q2 2026 vs. Q2 2025: Profit of US$5.6m vs. loss of US$42.8m (moved from loss to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.03 per share vs. a loss of US$0.25 per share (moved from loss to profit)
• Trailing 12 Month Net Income, Q2 2026 vs. Q2 2025: Loss of US$254.4m vs. loss of US$198.6m (loss widened over the year)

Prefer clear visuals over wading through dense earnings releases and spreadsheets? Get a complete view of Tempus AI with an easy-to-scan summary of its revenue and profit trends in the company report for Tempus AI.

Tempus AI bull case passes key platform tests

Bulls argue Tempus AI is shifting from a diagnostics heavy story to a data and applications platform with a real economic engine behind it. Q2 helps that claim. Data & Applications revenue reached US$93.2m and rose faster than Diagnostics, with data licensing and modeling up about 36%. Management highlighted US$200m of new bookings and multi year agreements with AstraZeneca, BioNTech, GSK, BMS and Merck, which supports the idea of “stickiness” in the Lens platform. The first multimodal foundation model for AstraZeneca cleared predefined acceptance criteria in both public and blinded trials, which is a concrete product milestone rather than just a research update. On profitability, Tempus AI moved to a US$5.6m GAAP profit and US$8m of adjusted EBITDA while cutting operating cash use to US$7.5m. That, combined with lower interest from the convertible refinancing, aligns with the narrative of economics moving toward breakeven.

Bear case on profits, leverage and dilution not retired

Bears focus on two points: profitability that does not yet look durable and financial risk from debt and acquisitions. Q2 shows some of those concerns still in play. Tempus AI is profitable this quarter, yet trailing 12 month net income remains a loss of US$254.4m and operating cash flow is still negative. The company refinanced into US$460m of zero coupon converts to remove a costly loan, which reduces interest expense but introduces future dilution risk if the stock performs well. The planned Personalis acquisition adds further execution and financing questions. Management plans to use stock and potentially new debt, and the target is currently loss making. Guidance for 2026 adjusted EBITDA of about US$65m and the aim for positive free cash flow lean against the thesis that the business cannot scale to profits, but those are future milestones that still need to be delivered.

Reveal whether Wall Street sees Tempus AI’s new bookings, cleaner balance sheet and first quarter of profit as the start of a real earnings reset or just a brief relief rally. Compare that internal progress with the street’s expectations in the consensus price target analysis for Tempus AI.

Stay Ahead With a Clear Plan

If Tempus AI’s first profitable quarter and cleaner balance sheet have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and wait for a setup that fits your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and keep focused on the key updates that matter to your holdings. For a longer term view, lean on the Community to see how other investors are thinking about the same risks and catalysts. That way you are spotting potential shifts early, both positive and negative, and giving yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Tempus AI?

Fresh stock ideas can move from quiet to flying quickly. Use these curated shortlists before the crowd catches on and while the data still matters most. Act now.

• Target steadier compounding potential with companies that pass strict balance sheet and fundamentals checks using our curated list of solid balance sheet and fundamentals stocks (45 results).
• Ride potential breakout momentum in smaller AI players that already generate real profits by scanning the hand picked 69 profitable AI stocks that aren't just burning cash.
• Lock onto possible income workhorses with high yields that aim to support payouts through stronger balance sheets by reviewing the carefully filtered 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.